Search

Your search keyword '"Zerbini, Cristiano"' showing total 13 results
Start Over Author "Zerbini, Cristiano" Publisher wiley
13 results on '"Zerbini, Cristiano"'

3. Efficacy and Safety of Long‐Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate

Author

Fleischmann, Roy, primary, Takeuchi, Tsutomu, additional, Schiff, Michael, additional, Schlichting, Douglas, additional, Xie, Li, additional, Issa, Maher, additional, Stoykov, Ivaylo, additional, Lisse, Jeffrey, additional, Martinez‐Osuna, Pindaro, additional, Rooney, Terence, additional, and Zerbini, Cristiano A. F., additional

Published
2020
Full Text
View/download PDF

5. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

Author

Geusens, Piet, primary, Marin, Fernando, additional, Kendler, David L, additional, Russo, Luis A, additional, Zerbini, Cristiano AF, additional, Minisola, Salvatore, additional, Body, Jean Jacques, additional, Lespessailles, Eric, additional, Greenspan, Susan L, additional, Bagur, Alicia, additional, Stepan, Jan J, additional, Lakatos, Péter, additional, Casado, Enrique, additional, Moericke, Rüdiger, additional, López‐Romero, Pedro, additional, and Fahrleitner‐Pammer, Astrid, additional

Published
2018
Full Text
View/download PDF

6. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

Author

Fleischmann, Roy, primary, Schiff, Michael, additional, van der Heijde, Désirée, additional, Ramos-Remus, Cesar, additional, Spindler, Alberto, additional, Stanislav, Marina, additional, Zerbini, Cristiano A. F., additional, Gurbuz, Sirel, additional, Dickson, Christina, additional, de Bono, Stephanie, additional, Schlichting, Douglas, additional, Beattie, Scott, additional, Kuo, Wen-Ling, additional, Rooney, Terence, additional, Macias, William, additional, and Takeuchi, Tsutomu, additional

Published
2017
Full Text
View/download PDF

8. Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes

Author

Dasgupta, Bhaskar, primary, Combe, Bernard, additional, Louw, Ingrid, additional, Wollenhaupt, Jürgen, additional, Zerbini, Cristiano A. F., additional, Beaulieu, Andre, additional, Schulze-Koops, Hendrik, additional, Durez, Patrick, additional, Wolff, Verónica, additional, Yao, Ruji, additional, Weng, Haoling H., additional, Govoni, Marinella, additional, and Vastesaeger, Nathan, additional

Published
2014
Full Text
View/download PDF

9. Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension

Author

Brown, Jacques P, primary, Reid, Ian R, additional, Wagman, Rachel B, additional, Kendler, David, additional, Miller, Paul D, additional, Jensen, Jens-Erik Beck, additional, Bolognese, Michael A, additional, Daizadeh, Nadia, additional, Valter, Ivo, additional, Zerbini, Cristiano AF, additional, and Dempster, David W, additional

Published
2014
Full Text
View/download PDF

10. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

Author

Kremer, Joel M., primary, Bloom, Bradley J., additional, Breedveld, Ferdinand C., additional, Coombs, John H., additional, Fletcher, Mark P., additional, Gruben, David, additional, Krishnaswami, Sriram, additional, Burgos-Vargas, Rubén, additional, Wilkinson, Bethanie, additional, Zerbini, Cristiano A. F., additional, and Zwillich, Samuel H., additional

Published
2012
Full Text
View/download PDF

11. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Author

Kremer, Joel M., primary, Bloom, Bradley J., additional, Breedveld, Ferdinand C., additional, Coombs, John H., additional, Fletcher, Mark P., additional, Gruben, David, additional, Krishnaswami, Sriram, additional, Burgos‐Vargas, Rubén, additional, Wilkinson, Bethanie, additional, Zerbini, Cristiano A. F., additional, and Zwillich, Samuel H., additional

Published
2009
Full Text
View/download PDF

13. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

Author

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, and Fleischmann R

Subjects
Adult, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid physiopathology, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Janus Kinase Inhibitors therapeutic use, Methotrexate therapeutic use, Piperidines therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use
Abstract

Objective: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the efficacy, including inhibition of structural progression, and safety of tofacitinib in patients with active RA and an inadequate response to methotrexate (MTX). Month 24 data from the completed study are reported here., Methods: Patients were randomized 4:4:1:1 to receive tofacitinib 5 mg or 10 mg twice daily, or placebo, switched to tofacitinib 5 mg or 10 mg twice daily, with stable background MTX. Patients receiving placebo switched to tofacitinib at month 3 (nonresponders) or month 6 (remaining patients). Clinical efficacy, structural progression, and treatment-emergent adverse events were evaluated. Analyses were performed on the full analysis set with observed data or nonresponder imputation with no advancement penalty for clinical efficacy, and imputation by linear extrapolation for structural progression., Results: Overall, 797 patients were treated; 539 (67.6%) completed 24 months of treatment. Responses according to the American College of Rheumatology criteria for 20% improvement (ACR20), ACR50, and ACR70; the proportion of patients in whom remission or low disease activity was achieved according to the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, Clinical Disease Activity Index, or Simplified Disease Activity Index; Boolean remission; and Health Assessment Questionnaire disability index scores were maintained from month 12 to 24 and were similar between tofacitinib dosages. Limited structural damage was observed at months 12 and 24. Safety events were similar in type and frequency for both tofacitinib dosages, and were consistent with those previously reported., Conclusion: Our findings indicate that clinical and radiographic treatment effects are sustained in months 12-24 in patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX. The safety profile is consistent with that of other tofacitinib studies., (© 2019 Pfizer Inc. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results